Phase II and Tumor Pharmacodynamic Study of Gefitinib in Patients with Advanced Breast Cancer
José Baselga(Universitat Autònoma de Barcelona), Federico Rojo(Hospital Universitario Fundación Jiménez Díaz)
Cited by 409
Related Papers
Expression of p95HER2, a Truncated Form of the HER2 Receptor, and Response to Anti-HER2 Therapies in Breast Cancer
|JNCI Journal of the National Cancer Institute|2007|876
Targeted therapies for breast cancer
|Journal of Clinical Investigation|2011|371
Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225)
|Clinical Cancer Research|2004|277
PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
|Oncotarget|2015|100
Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer
|Molecular Cancer Therapeutics|2011|52